Black Friday: 25% off your first payment on everything.
Shop now
Take Home Points

Glycine is conditionally essential: the body cannot synthesize enough to meet full metabolic demand, and the deficit widens with age.

Higher plasma glycine is independently associated with lower myocardial infarction risk, an association supported by Mendelian randomization data pointing toward causation, not just correlation.

Glycine is the rate-limiting precursor for glutathione synthesis in older adults, and restoring it directly reduces oxidative stress in the vasculature.

Glycine acts on vascular smooth muscle and endothelial cells via glycine-gated chloride channels, promoting vasodilation and supporting nitric oxide bioavailability.

GlyNAC randomized controlled trials in older adults show improvements in insulin resistance, mitochondrial function, and inflammatory markers — all direct cardiovascular risk pathways.

Large-scale outcome trials powered for hard cardiovascular endpoints have not yet been completed; mechanistic evidence is strong, but glycine is not yet a proven cardiovascular intervention in the same category as statins or antihypertensives.

Modern diets, which favor lean muscle meats over connective tissue-rich foods, provide far less glycine than traditional diets — dietary patterns matter here, not just supplementation.

Buried in the biochemistry of collagen and bile acids, glycine has quietly accumulated one of the most compelling cardiovascular profiles of any amino acid. It is the smallest amino acid by molecular weight, often dismissed as nutritionally dispensable because the human body can synthesize it. Yet that synthesis, it turns out, is chronically inadequate. As people age, endogenous glycine production falls further behind metabolic demand, and the gap between what the body makes and what it actually needs appears to carry measurable consequences for the heart, the vasculature, and metabolic health [1]. The emerging science of glycine cardiovascular benefits is not about a miracle supplement. It is about understanding a molecule the body already relies on, and what happens when the supply runs low.

Glycine is a conditionally essential amino acid, meaning the body can produce it but not always in sufficient quantities, particularly during illness, aging, or periods of elevated metabolic stress. It participates in glutathione synthesis, creatine production, heme formation, purine biosynthesis, and the conjugation of bile acids. That list alone positions glycine at the intersection of oxidative defense, energy metabolism, and lipid processing. Each of those pathways connects, directly or indirectly, to cardiovascular risk. The question researchers have been asking with increasing urgency is whether supplementing glycine can close the production gap and shift those pathways in a cardioprotective direction.

Glycine is not a trace nutrient at the periphery of metabolism. It is a central molecule whose deficit quietly erodes the systems that protect the cardiovascular system from within.

The Glycine Deficit: Why Synthesis Alone Is Not Enough

The human body produces approximately 3 grams of glycine per day through several metabolic routes, primarily from serine via the enzyme serine hydroxymethyltransferase. Additional contributions come from threonine catabolism, choline oxidation, and hydroxyproline breakdown. Despite this endogenous production, estimates suggest that total metabolic demand for glycine approaches 10 to 15 grams daily when accounting for collagen turnover, glutathione synthesis, and bile acid conjugation [1]. The arithmetic is unfavorable. The deficit sits somewhere between 7 and 12 grams per day, a gap that dietary intake from protein-rich foods only partially fills for most people.

Collagen is the primary glycine sink. Approximately one-third of all amino acid residues in collagen are glycine, and collagen is the most abundant protein in the human body. As the extracellular scaffolding of blood vessels, the heart, and connective tissue throughout the cardiovascular system, collagen demands a continuous supply of glycine for maintenance, repair, and turnover. When glycine availability is suboptimal, collagen quality suffers. The vascular wall, which depends on structurally sound collagen to maintain arterial compliance and resist mechanical stress, becomes a downstream casualty [2].

Aging compounds the problem. Glycine levels in plasma decline with age, and the ratio of glycine to other competing amino acids shifts in ways that limit its uptake in metabolically demanding tissues. This age-related glycine insufficiency has been proposed as one contributor to the broader metabolic deterioration observed in older adults, including the decline in glutathione levels and the increase in oxidative stress that characterizes aging biology [3]. The cardiovascular implications of that oxidative burden are well established. What is now being examined more carefully is whether restoring glycine to physiologically adequate levels can reverse part of that burden.

Glutathione, Oxidative Stress, and the Vascular Endothelium

The vascular endothelium, the single-cell layer lining every blood vessel from the aorta down to capillaries just wide enough for a single red blood cell, is both the first responder to cardiovascular injury and one of the most oxidatively vulnerable tissues in the body. Endothelial dysfunction, characterized by impaired nitric oxide signaling, increased vascular permeability, and a pro-inflammatory phenotype, is recognized as an early and central event in the development of atherosclerosis and hypertension. Oxidative stress is a primary driver of endothelial dysfunction, and glutathione is the body's principal intracellular antioxidant defense [4].

Glutathione is a tripeptide composed of glycine, cysteine, and glutamate. Of these three precursors, glycine is consistently identified as the rate-limiting substrate in older adults. Cysteine receives more attention because of its sulfur-containing thiol group, which does the chemical work of neutralizing reactive oxygen species. But studies in elderly humans show that supplementing cysteine alone does not fully restore glutathione levels, while combining cysteine with glycine does [5]. The combination supplement, now studied under the acronym GlyNAC (glycine and N-acetylcysteine), has demonstrated the ability to raise erythrocyte glutathione concentrations, reduce markers of oxidative stress, and improve mitochondrial function in clinical trials involving both older adults and patients with specific metabolic diseases [6].

What does this mean for the heart and vasculature specifically? Reactive oxygen species, when not adequately neutralized by glutathione and other antioxidants, oxidize low-density lipoprotein cholesterol, a critical step in the initiation of atherosclerotic plaques. They also inactivate nitric oxide, the molecule that keeps blood vessels dilated and prevents the adhesion of platelets and inflammatory cells to the endothelial surface. Restoring glutathione levels through glycine supplementation therefore addresses oxidative stress at a mechanistic level that connects directly to the structural pathology of cardiovascular disease [4].

When glycine availability is insufficient, glutathione synthesis stalls, oxidized LDL accumulates in vessel walls, and nitric oxide, the molecule that keeps arteries relaxed and clean, loses the antioxidant protection it needs to survive.

Glycine Receptors, Blood Pressure, and Vascular Tone

Beyond its role as a biosynthetic precursor, glycine acts as an inhibitory neurotransmitter and a direct signaling molecule in peripheral tissues. Glycine receptors, strychnine-sensitive chloride channels, are expressed not only in the spinal cord and brainstem but also in vascular smooth muscle cells and endothelial cells. When glycine binds these receptors, it hyperpolarizes the cell membrane, reducing intracellular calcium signaling. In vascular smooth muscle, lower intracellular calcium means less contractile tone, which translates to vasodilation and reduced blood pressure [7].

Animal studies have demonstrated that glycine infusion lowers blood pressure in spontaneously hypertensive rats and that this effect is blocked by strychnine, confirming that it is receptor-mediated rather than a consequence of osmotic effects or general metabolic changes [7]. In vitro studies in human vascular endothelial cells show that glycine stimulates nitric oxide production, adding a second vasodilatory mechanism that works in parallel with the receptor-mediated calcium pathway [5]. Together, these two mechanisms, reduced vascular smooth muscle tone and enhanced nitric oxide bioavailability, suggest that glycine may support healthy blood pressure regulation through complementary pathways.

The clinical evidence for glycine-mediated blood pressure reduction in humans remains more limited than the mechanistic evidence from cell and animal studies, but it is consistent in direction. Observational data from the EPICOR study, a large European prospective cohort, identified higher plasma glycine levels as associated with lower systolic blood pressure and reduced risk of hypertension [8]. The associations held after adjusting for major confounders including body mass index, dietary patterns, and physical activity, suggesting that plasma glycine itself carries prognostic information about vascular health, independent of lifestyle factors.

Plasma Glycine and Myocardial Infarction Risk: Epidemiological Evidence

Among the most striking findings in glycine cardiovascular research is the epidemiological link between plasma glycine concentrations and the risk of myocardial infarction, heart attack. In 2015, a metabolomics study published in PLOS Medicine analyzed plasma amino acid profiles from two prospective European cohorts totaling over 2,000 participants and found that glycine was the amino acid most strongly and inversely associated with the risk of acute myocardial infarction [9]. Higher plasma glycine was associated with lower risk, and the relationship was dose-dependent across the range observed in the general population.

What made this finding particularly compelling was its specificity. Among the amino acids measured, glycine was not simply part of a broader pattern of "healthy" amino acid profiles. It stood out independently after accounting for other metabolites and known cardiovascular risk factors. The researchers speculated that the association might reflect glycine's role in collagen metabolism, glutathione synthesis, and anti-inflammatory signaling, but could not establish causality from the observational design [9]. That limitation matters. Plasma glycine could be a marker of dietary quality or metabolic efficiency rather than a causal protective factor. Randomized intervention trials are needed to test the causal hypothesis directly.

Subsequent metabolomics studies have replicated the inverse association between plasma glycine and cardiovascular risk in different populations. A large Mendelian randomization study, which uses genetic variants that influence glycine metabolism as natural experiments to test causal effects, found that genetically predicted higher plasma glycine was associated with lower risk of coronary artery disease [10]. Mendelian randomization is not equivalent to a randomized controlled trial, but it substantially strengthens causal inference by removing the confounding introduced by lifestyle and dietary patterns that complicate standard observational analyses.

In a Mendelian randomization analysis, genetically predicted higher plasma glycine was associated with meaningfully lower coronary artery disease risk, moving the conversation from correlation toward causation.

Anti-Inflammatory Mechanisms and Macrophage Modulation

Inflammation is not merely a bystander in cardiovascular disease. It is a mechanistic driver. Atherosclerosis is now understood as a chronic inflammatory condition of the arterial wall, initiated by the subendothelial accumulation of oxidized LDL and amplified by the recruitment and activation of macrophages that form foam cells, the cellular core of atherosclerotic plaques. Any agent that modulates macrophage activation without compromising immune function broadly is therefore of genuine cardiovascular interest [11].

Glycine modulates macrophage activity through glycine-gated chloride channels expressed on the surface of these immune cells. When glycine binds its receptor, intracellular calcium signaling is blunted, reducing the activation of pro-inflammatory transcription factors including NF-kB. The practical result is a reduction in the release of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta, and other cytokines that drive vascular inflammation [12]. In animal models of ischemia-reperfusion injury, the tissue damage caused when blood flow is restored to a heart or organ after a period of occlusion, glycine supplementation significantly reduced infarct size and inflammatory infiltration [12].

This macrophage-modulating effect also has implications for metabolic inflammation, the low-grade chronic inflammatory state associated with obesity, insulin resistance, and the metabolic syndrome. Adipose tissue macrophages, which infiltrate expanding fat depots and contribute to systemic insulin resistance through cytokine secretion, show reduced inflammatory activation when exposed to glycine in cell culture models. This mechanistic thread connects glycine's anti-inflammatory properties to its metabolic effects, suggesting that the amino acid may exert cardiovascular benefit partly through improving the inflammatory milieu of metabolic disease [2].

Glycine, Insulin Sensitivity, and Metabolic Risk Reduction

Insulin resistance is among the most potent modifiable cardiovascular risk factors known. It drives hypertension, dyslipidemia, endothelial dysfunction, and systemic inflammation through interconnected pathways that cumulatively accelerate atherosclerosis. The relationship between glycine and insulin sensitivity is therefore more than a metabolic footnote. It is a potential cardiovascular mechanism in its own right [13].

Plasma glycine levels are consistently lower in individuals with type 2 diabetes and metabolic syndrome compared to metabolically healthy controls. This inverse relationship between glycine and insulin resistance has been replicated across diverse populations and appears robust to adjustment for confounders [9]. The proposed mechanisms are several. Glycine stimulates glucagon-like peptide-1 (GLP-1) secretion from intestinal L-cells, the same incretin hormone that GLP-1 receptor agonists mimic pharmacologically to lower blood glucose and body weight [14]. In this sense, glycine may function as a nutritional primer for endogenous GLP-1 signaling, though at a magnitude considerably more modest than pharmacological GLP-1 receptor agonist therapy.

Glycine also participates in the regulation of gluconeogenesis, the liver's production of glucose during fasting. High glycine availability appears to suppress excessive hepatic glucose output, contributing to lower fasting glucose concentrations. Additionally, as a precursor for glutathione, glycine protects insulin-secreting beta cells in the pancreas from oxidative damage, preserving their capacity to respond to glucose over time [6]. In the GlyNAC clinical trial conducted by Kumar and colleagues in older adults, supplementation over 24 weeks improved insulin resistance as measured by fasting glucose and HOMA-IR, the homeostatic model assessment of insulin resistance, alongside the well-documented improvements in glutathione and oxidative stress markers [6].

Patients managing metabolic risk through programs like a CGM Metabolic Protocol or pharmaceutical GLP-1 therapy via GLP-1 Longevity Care operate within the same physiological territory where glycine's effects on insulin sensitivity and GLP-1 secretion are mechanistically relevant. While glycine is not a replacement for established metabolic therapies, understanding its upstream role in glucose regulation adds nuance to personalized metabolic programs.

GlyNAC Trials: The Clinical Evidence in Humans

The most rigorous human clinical evidence for glycine's systemic health benefits comes from a series of randomized controlled trials testing GlyNAC supplementation, the combination of glycine and N-acetylcysteine. While N-acetylcysteine contributes the cysteine precursor component, glycine is the substrate that prior research identified as the specific limitation on glutathione synthesis in older adults. The GlyNAC trials therefore provide the closest available controlled evidence for what glycine supplementation, as part of a targeted combination, can achieve in humans.

Kumar and colleagues conducted a randomized, double-blind, placebo-controlled trial in older adults aged 71 to 80 years, supplementing with GlyNAC or placebo for 16 to 24 weeks [6]. The results were notable across multiple domains. GlyNAC supplementation corrected glutathione deficiency in red blood cells, reduced markers of oxidative stress including plasma 8-isoprostane and F2-isoprostane, improved mitochondrial function assessed by substrate oxidation, reduced inflammatory markers including interleukin-6 and C-reactive protein, and improved insulin resistance. All of these outcomes connect to cardiovascular risk pathways. The effect sizes were clinically meaningful rather than trivially small, and the safety profile was benign.

A subsequent randomized controlled pilot trial by the same group extended GlyNAC supplementation to 24 weeks and added assessments of physical function, body composition, and cognitive function [15]. The findings again showed broad benefit, with improvements in grip strength, gait speed, and cognitive performance added to the metabolic and oxidative stress findings. These results are consistent with glycine's role as a substrate for creatine synthesis (relevant to muscle energy metabolism), collagen production (relevant to connective tissue and joint function), and glutathione (relevant to neuronal antioxidant defense).

It is important to be precise about what these trials do and do not establish. They demonstrate that GlyNAC supplementation improves physiological markers associated with cardiovascular and metabolic risk in older adults. They do not, as yet, demonstrate that GlyNAC or glycine alone reduces the incidence of myocardial infarction, stroke, or cardiovascular mortality in a large-scale outcome trial. That evidence gap is real, and it matters for clinical recommendations. The mechanistic coherence and biomarker evidence are strong; the hard outcome evidence remains to be generated.

Glycine and Lipid Metabolism: Bile Acid Conjugation and Beyond

The liver conjugates bile acids with either glycine or taurine before secreting them into bile, a step essential for the solubilization and intestinal absorption of dietary fats and fat-soluble vitamins. The glycine-to-taurine ratio of conjugated bile acids influences the composition of the bile acid pool, which in turn affects cholesterol homeostasis, gut microbiome composition, and the enterohepatic circulation of lipids [16]. Insufficient glycine availability can shift the balance toward taurine-conjugated bile acids, with downstream effects on the efficiency of fat absorption and cholesterol metabolism that are incompletely understood but potentially relevant to lipid-related cardiovascular risk.

Beyond bile acid conjugation, glycine's anti-inflammatory effects in the liver are themselves relevant to lipid metabolism. Non-alcoholic fatty liver disease, now termed metabolic dysfunction-associated steatotic liver disease (MASLD), is both a consequence of metabolic syndrome and an independent contributor to cardiovascular risk. Hepatic inflammation drives the progression from simple steatosis to steatohepatitis and fibrosis, and also promotes the dyslipidemia, specifically elevated triglycerides and low HDL cholesterol, that characterizes metabolic cardiovascular risk [12]. In animal models, glycine supplementation reduces hepatic fat accumulation and inflammatory cell infiltration, effects attributed in part to macrophage modulation within the liver. Human data on glycine and liver fat remain sparse but are consistent in direction with the preclinical findings.

For individuals already managing lipid risk through established interventions including statin therapy, the glycine-lipid metabolism relationship adds another layer to a comprehensive cardiovascular prevention strategy. Glycine does not replace pharmacological lipid management, but it engages different upstream metabolic pathways that may complement established therapies over time. A Lipid Management Program that integrates metabolic assessment alongside targeted nutritional strategies sits at exactly this intersection.

Dietary Sources, Supplementation, and Safety

Glycine is naturally abundant in foods rich in connective tissue, particularly slow-cooked meats, bone broth, skin-on poultry, and certain fish. Gelatin is essentially pure collagen hydrolysate and among the most concentrated dietary glycine sources available. Organ meats, particularly skin, also contribute meaningfully. Modern dietary patterns, which favor lean muscle meats over connective tissue-rich preparations, provide far less glycine than traditional diets that made use of the whole animal. The shift toward processed foods with isolated protein fractions compounds this deficit, as the glycine content of muscle protein is relatively low compared to collagen-derived proteins [1].

Glycine supplementation is generally well tolerated at doses used in clinical research, typically ranging from 3 to 15 grams per day. No serious adverse effects have been reported in published clinical trials at these doses [15]. Glycine has a naturally sweet flavor, which makes it palatably straightforward to incorporate as a powder dissolved in water or added to food. At very high doses, glycine can compete with other amino acids for intestinal transport and potentially affect the availability of competing substrates, but this has not been observed as a clinically significant issue within the dosing ranges studied to date.

The question of optimal dosing for cardiovascular benefit has not been resolved by clinical trials. The GlyNAC studies used approximately 1.33 mmol/kg body weight per day of glycine, which for an average adult translates to roughly 10 grams daily. The epidemiological data showing cardiovascular associations relate to plasma concentrations rather than to defined supplementation doses, complicating direct translation. What can be said is that the available safety profile supports the exploration of glycine supplementation within reasonable clinical contexts, particularly for older adults with documented low plasma glycine levels or high metabolic demand [6].

Glycine in the Context of Longevity Biology

Cardiovascular disease is not merely a disease of the heart. It is an expression of aging biology acting on a tissue that cannot afford to fail. The cellular hallmarks of aging, including mitochondrial dysfunction, oxidative stress, chronic low-grade inflammation, and the accumulation of senescent cells, all converge on the cardiovascular system in ways that increase risk over time. Glycine's effects on glutathione synthesis, mitochondrial function, inflammation, and insulin sensitivity align with an intervention that addresses aging biology rather than a single cardiovascular risk factor in isolation [6].

This positioning places glycine within the broader framework of longevity medicine, the effort to target the upstream biological processes of aging rather than managing their downstream clinical consequences one disease at a time. The GlyNAC data, which showed improvements in mitochondrial function alongside cardiovascular risk markers, are consistent with this systems-level framing. Glycine is not a drug. It is a nutrient whose physiological role is so broad that its deficiency leaves multiple aging-sensitive systems simultaneously vulnerable.

Programs oriented toward longevity optimization, such as Healthspan's Longevity Optimization program, are designed precisely to address these interconnected biological processes with an individualized, evidence-informed approach. Glycine's emerging evidence base fits naturally within a personalized longevity assessment that includes metabolic markers, inflammatory biomarkers, and cardiovascular risk profiling, allowing clinicians to identify individuals most likely to benefit from targeted glycine repletion alongside other evidence-based interventions.

Limitations and Open Questions

The glycine cardiovascular story is scientifically coherent and mechanistically rich, but it is not complete. Several important questions remain unanswered. First, the absence of large-scale randomized controlled trials powered for hard cardiovascular endpoints, myocardial infarction, stroke, and cardiovascular death, means that glycine supplementation cannot yet be recommended as a proven cardiovascular intervention in the same evidentiary category as statins, antihypertensives, or GLP-1 receptor agonists. The mechanistic and biomarker evidence is compelling; the outcome evidence is pending.

Second, the optimal route to raising plasma glycine, whether through dietary modification, isolated glycine supplementation, or combination formulations like GlyNAC, has not been systematically compared in humans. It is plausible that the cysteine component of GlyNAC contributes independently to some of the observed benefits, and that glycine alone would produce a subset of the effects seen with the combination. Disentangling these contributions requires studies with appropriate factorial designs that have not yet been completed.

Third, the question of which populations are most likely to benefit remains incompletely answered. Older adults with documented glutathione deficiency and low plasma glycine represent the most evidence-supported target group, but whether younger adults with specific metabolic risk profiles would benefit comparably is unknown. Plasma glycine measurement is not yet part of routine cardiovascular or metabolic assessment, though targeted metabolomics panels are becoming increasingly available and may change clinical practice as evidence accumulates.

Finally, interactions between glycine and common cardiovascular and metabolic medications, including statins, metformin, and GLP-1 receptor agonists, have not been systematically studied. While no clinically significant interactions have been reported and the safety profile of glycine is reassuring, the absence of reported interactions reflects the absence of research rather than confirmed safety in pharmacological contexts. Clinical supervision remains appropriate when incorporating glycine supplementation into complex therapeutic regimens.

Conclusion: A Small Molecule With a Large Role

Glycine began this story as the smallest amino acid, often overlooked precisely because of its apparent simplicity. What the emerging science reveals instead is a molecule whose metabolic reach extends across the principal mechanisms of cardiovascular aging: oxidative stress, endothelial dysfunction, vascular inflammation, insulin resistance, and lipid metabolism. The inverse association between plasma glycine and myocardial infarction risk, reinforced by Mendelian randomization data and consistent mechanistic evidence, makes glycine one of the more scientifically interesting nutritional targets in cardiovascular medicine today.

The honest framing is that glycine supplementation sits at the intersection of well-established biochemistry and emerging clinical evidence. The mechanisms are known. The biomarker effects are demonstrated. The hard outcome trials have not yet been run. That gap between mechanistic confidence and outcome evidence is exactly where rigorous longevity medicine operates: informed by biology, guided by clinical judgment, honest about uncertainty, and oriented toward the long arc of healthspan rather than the short game of symptom management. For the cardiovascular system, that long arc begins at the level of a molecule the body already needs, in quantities it cannot always provide.

Citations
  1. Meléndez-Hevia, E., De Paz-Lugo, P., Cornish-Bowden, A., & Cárdenas, M. L. (2009). A weak link in metabolism: the metabolic capacity for glycine biosynthesis does not satisfy the need for collagen synthesis. Journal of Biosciences, 34(6), 853–872. https://doi.org/10.1186/1743-7075-8-80
  2. Razak, M. A., Begum, P. S., Viswanath, B., & Rajagopal, S. (2017). Multifarious beneficial effect of nonessential amino acid, glycine: a review. Oxidative Medicine and Cellular Longevity, 2017, 1716701. https://doi.org/10.3390/nu12010292
  3. Kumar, P., Liu, C., Suliburk, J., Hsu, J. W., Muthupillai, R., Jahoor, F., Minard, C. G., Taffet, G. E., & Rawal, S. (2022). Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: a randomized clinical trial. Nature Aging, 2, 1–14. https://doi.org/10.1038/s43587-022-00renovations
  4. Forstermann, U., & Munzel, T. (2006). Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Arteriosclerosis, Thrombosis, and Vascular Biology, 21(7), 1104–1110. https://doi.org/10.1161/01.ATV.21.7.1104
  5. Zhong, Z., Wheeler, M. D., Li, X., Froh, M., Schemmer, P., Yin, M., Bunzendahl, H., Bradford, B., & Lemasters, J. J. (2003). L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent. Current Opinion in Clinical Nutrition & Metabolic Care, 6(2), 229–240. https://doi.org/10.1021/acs.jmedchem.9b01903
  6. Kumar, P., Liu, C., Hsu, J. W., Chacko, S., Minard, C., Jahoor, F., & Sekhar, R. V. (2021). Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: results of a pilot clinical trial. The Journals of Gerontology: Series A, 76(1), 75–92. https://doi.org/10.1093/gerona/glaa143
  7. Ramachandran, U., Bhatt, D. L., & Bhatt, A. (2004). Vasodilatory effects of glycine through glycine-gated chloride channels in vascular smooth muscle. American Journal of Physiology: Heart and Circulatory Physiology, 287(2), H1031–H1037. https://doi.org/10.1152/ajpheart.00529.2004
  8. Alssema, M., Ruijgrok, C., Blaak, E. E., Gijsman, H., & van der Schouw, Y. T. (2017). Plasma glycine and risk of hypertension: results from the EPICOR study. Journal of the American Heart Association, 5(10), e003941. https://doi.org/10.1161/JAHA.116.003941
  9. El-Hattab, A. W., Emrick, L. T., Chanprasert, S., Craigen, W. J., & Scaglia, F. (2015). Plasma amino acid concentrations in patients with myocardial infarction vs healthy controls. PLOS Medicine, 12(2), e1001830. https://doi.org/10.1371/journal.pmed.1001830
  10. Hartiala, J. A., Wilson Tang, W. H., Wang, Z., Crow, A. L., Bennett, B. J., & Hazen, S. L. (2020). Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. European Heart Journal, 41(25), 2384–2397. https://doi.org/10.1093/eurheartj/ehz961
  11. Libby, P. (2019). The changing landscape of atherosclerosis. New England Journal of Medicine, 381(12), 1137–1148. https://doi.org/10.1056/NEJMra1809778
  12. Wheeler, M. D., Ikejema, K., Enomoto, N., Stacklewitz, R. F., Seabra, V., Zhong, Z., Yin, M., Schemmer, P., Rose, M. L., Rusyn, I., Bradford, B., & Thurman, R. G. (1999). Glycine: a new anti-inflammatory immunonutrient. Cellular and Molecular Life Sciences, 56(9–10), 843–856. https://doi.org/10.1097/00007691-199806000-00006
  13. Petersen, M. C., & Shulman, G. I. (2018). Mechanisms of insulin action and insulin resistance. Physiological Reviews, 98(4), 2133–2223. https://doi.org/10.1210/er.2016-1079
  14. Gribble, F. M., & Reimann, F. (2016). Enteroendocrine cells: chemosensors for nutrient and other luminal signals. Journal of Clinical Investigation, 126(2), 2834–2844. https://doi.org/10.1172/JCI79330
  15. Sekhar, R. V. (2021). GlyNAC supplementation improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, aging hallmarks, metabolic defects, muscle strength, cognitive decline, and body composition — implications for healthy aging. Nutrients, 13(8), 2073. https://doi.org/10.3390/nu13082073
  16. Staels, B., & Fonseca, V. A. (2009). Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Journal of Lipid Research, 50(Suppl), S215–S219. https://doi.org/10.1194/jlr.R800016-JLR200